Ulteriori informazioni
Dieses Buch, geschrieben von Fachexperten auf dem Gebiet, fasst den aktuellen Stand der Wissenschaft im Hinblick auf phänotypische und zielorientierte Ansätze der Entwicklung von Arzneistoffen gegen pathogene Protozoen zusammen. Der Schwerpunkt liegt dabei vor allem auf virtuellen Substanzen und dem Hochdurchsatz-Screening, auf Naturprodukten, dem computergestützten Design von Arzneistoffen, dem strukturgestützten Design von Arzneistoffen, der Identifizierung von Wirkmechanismen und dem Pathway-Modelling. Weiterhin werden moderne "omik"-Technologien sowie enzymatische Drug Targets erörtert. Mathematische, auf der Systembiologie basierende Ansätze werden als neue Methoden für die Auflösung komplexer Mechanismen, die Pathogene überleben lassen, und für die Target-Identifizierung vorgestellt. Präsentiert werden darüber hinaus neu entwickelte Wirkstoffe, die über bestimmte Pathways Parasiten abtöten und als Leitsubstanzen für weitere Arzneimittelentwicklungen dienen.
Sommario
Discovering the mechanism of action of novel compounds that target unicellular eucaryotic parasitesContribution of Natural Products to drug discovery in tropical diseasesIsoxazolines as effective ectoparasiticidesTrypanosomal Cysteine Proteases: Target Validation and Drug Design StrategiesPotential of pyrimidine metabolism for antitrypanosomal drug discoveryThe Kennedy pathways for phospholipid biosynthesis in PlasmodiumImmunophilins as possible drug targetsAutophagy in Plasmodium/invasion of Plasmodium The glideosome: the locomotive complex behind gliding motility and invasionTurnover of glycosomes in trypanosomes. Perspectives for drug discoveryN-myristoyltransferase as a target for Drug Discovery in MalariaIntermediary carbon metabolism of Plasmodium revisitedThe role of metabolomics in antiparasitic drug discoveryMethods to investigate system biology in TrypanosomaThe importance of targeting lipid metabolism in parasites for drug discoveryEpigenetic gene regulation: a key to development and survival of malaria parasitesEmerging importance of t-RNA synthetases as anti-malarial drug targetsUnderstanding protozoan parasite metabolism and identifying drug targets through flux balance analysisAttacking blood-borne parasites with mathematicsKinetic modeling of metabolism and drug target identification in ApicomplexaAntiparasitics from algaeMechanisms regulating transcription in Plasmodium falciparum as targets for novel antimalarial drugs
Info autore
Volume Editors:
Prof. Sylke Müller received her PhD in 1991 from the University of Hamburg. In 1992 she worked at the London School of Hygiene and Tropical Medicine, before returning to the Bernhard Nocht Institute for Tropical Medicine in Hamburg in 1994. In 1999 she was awarded the Habilitation and the venia legendi. From 2001 to 2012 she was funded by a Wellcome Trust Senior Fellowship at Dundee University (until 2004) and the University of Glasgow (2004 to 2012). In 2006 she was awarded a Personal Chair in Molecular and Biochemical Parasitology at the University of Glasgow.
Prof. Rachel Cerdan received her PhD from the University of Paris XI in 1997. She spent three years at the Laboratory of Molecular Biology (Medical Research Council) in Cambridge, UK as a Marie Curie post-doctoral fellow. She then moved to the Centre of Structural Biochemistry in Montpellier, France. In 2003, she joined the laboratory of Dynamics of Membrane Interactions in Normal and Pathological Cells in Montpellier. Currently, she is professor in biochemistry and structural biology at the University of Montpellier, France. Her current projects focus on the biochemical and structural characterization of pharmacological targets to develop new classes of antimalarials.
Prof. Ovidiu Radulescu studied physics and mathematics in Bucharest and Paris and obtained his PhD in 1994 from the University of Paris XI, France. Immediately after his PhD, he worked in theoretical condensed matter physics, first in the Institute of Theoretical Physics in Nijmegen, the Netherlands, and then in the Physics Department of the University of Leeds, UK. In 1999 he joined as a lecturer the Department of Mathematics of the University of Rennes 1, France. At that time, he was also associate member of the French Institute for Research in Computer Science and Automation, INRIA.
Since 2009, he is Professor in Systems Biology and team leader at the University of Montpellier, France. His team is part of the laboratory DIMNP UMR5235, whose main focuses are in parasitology and immunology.
Series Editor:
Prof. Paul M. Selzer studied biology, parasitology, and biochemistry at the University of Tübingen,
Germany, where he also received his PhD in biochemistry. He spent three years at the Molecular Design Institute and the Parasitology and Tropical Disease Research Laboratory at the University of California, San Francisco. During his career he has worked as a researcher and scientific manager for several pharmaceutical companies, and is currently Head of Antiparasitics R&D at Boehringer Ingelheim Animal Health, Germany. He is also a visiting professor at the Interfaculty Institute of Biochemistry of the University of Tübingen, and an honorary professor of the Department of Infection, Immunity, and Inflammation at the University of Glasgow, UK.
Riassunto
Dieses Buch, geschrieben von Fachexperten auf dem Gebiet, fasst den aktuellen Stand der Wissenschaft im Hinblick auf phänotypische und zielorientierte Ansätze der Entwicklung von Arzneistoffen gegen pathogene Protozoen zusammen. Der Schwerpunkt liegt dabei vor allem auf virtuellen Substanzen und dem Hochdurchsatz-Screening, auf Naturprodukten, dem computergestützten Design von Arzneistoffen, dem strukturgestützten Design von Arzneistoffen, der Identifizierung von Wirkmechanismen und dem Pathway-Modelling. Weiterhin werden moderne "omik"-Technologien sowie enzymatische Drug Targets erörtert. Mathematische, auf der Systembiologie basierende Ansätze werden als neue Methoden für die Auflösung komplexer Mechanismen, die Pathogene überleben lassen, und für die Target-Identifizierung vorgestellt. Präsentiert werden darüber hinaus neu entwickelte Wirkstoffe, die über bestimmte Pathways Parasiten abtöten und als Leitsubstanzen für weitere Arzneimittelentwicklungen dienen.
